Shanghai MicuRx Pharmaceutical Co., Ltd. engages in the experimenting, discovering, and development of innovative medicines. Its product pipelines focus on the treatment of resistant Gram-positive and Gram-negative bacterial infections. The company was founded by Zheng Yu Yuan and Mikhail F. Gordeev on August 7, 2012 and is headquartered in Shanghai, China.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company